Table 3.

The association between hyperuricemia and MAFLD by the Cox regression in the longitudinal cohort study.

Baseline hyperuricemia to subsequent MAFLD			Baseline MAFLD to subsequent hyperuricemia
	HR(95%CI)	P-value		HR(95%CI)	P-value
Crude	2.670 (2.307,3.090)	<0.001	Crude	1.765 (1.594,1.955)	<0.001
Model 1	2.192 (1.887,2.546)	<0.001	Model 1	1.395 (1.257,1.549)	<0.001
Model 2	1.766 (1.512,2.061)	<0.001	Model 2	1.255 (1.116,1.412)	<0.001
Model 3	1.765 (1.512,2.060)	<0.001	Model 3	1.245 (1.106,1.400)	<0.001

MAFLD, metabolic dysfunction-associated fatty liver disease.

Model 1: adjusted for age and sex.

Model 2: adjusted for age, sex, low-density lipoprotein cholesterol (LDL-C), fasting blood glucose (FBG), alanine aminotransferase (ALT), blood urea nitrogen (BUN), systolic blood pressure (SBP), triglycerides (TG).

Model 3: adjusted for age, sex, low-density lipoprotein cholesterol (LDL-C), fasting blood glucose (FBG), alanine aminotransferase (ALT), blood urea nitrogen (BUN), systolic blood pressure (SBP), triglycerides (TG), insulin resistance.